Posted by Michael Wonder on 08 Feb 2023
Appili Therapeutics announces that FDA accepts the ATI-1501 NDA
8 February 2023 - ATI-1501, liquid oral reformulation of the antibiotic metronidazole, receives PDUFA action date of 23 September 2023.
Appili Therapeutics today, with its partner Saptalis Pharmaceuticals, announced that the FDA accepted the ATI-1501 new drug application.
